Figure 5. Expression of AGR2 increases with prostate cancer progression and inversely correlates with EBP1 expression.
A, Left panel, box plots of immunohistochemical staining intensity of AGR2 in normal prostate tissue (n=42) or tissues from patients with prostate cancer (n=153). For all panels, the box represents the s.d. of the distribution, and the line through that box represents the mean of the distribution. The horizontal lines above and below the box represent the extreme values of the distribution. Middle panel, Correlation of AGR2 staining intensity with EBP1 staining intensity. Right panel, Correlation of AGR2 staining intensity with EBP1 proportion score (PS) (percentages of cells stained with EBP1: 1,<5%; 2, 5–30%; 3,31–70%; 4, >70%). B, representative staining of AGR2 in benign tissues (left panel), moderately malignant carcinomas (middle panel, Gleason 3+3) and highly malignant carcinomas (right panel, Gleason 4+5). C, Left panel, a public dataset ???? shows the average gene expression level at three different stages(benign n=23, primary n=64 and metastatic n=250) of prostate cancer. Right panel, scatter-plots of AGR2 versus EBP1 expression units in all these samples.